1. Introduction {#s0005}
===============

Ankylosing spondylitis (AS) is an inflammatory rheumatic disorder and a prototype of spondyloarthritis, characterized by axial skeleton and sacroiliac joint involvement ([@b0100]). Genetic, environmental factors and immune-mediated mechanisms play role in the pathogenesis of AS. Proinflammatory cytokines (Tumor necrosis factor \[TNF\]-α, Interleukin \[IL\]-1, IL-6 etc.), T cells and macrophages were observed in the cartilage of AS patients. Also, TNF-α serum levels were significantly higher in AS patients ([@b0050], [@b0075]). TNF-α expression in cartilage and serum provided grounds for TNF-α inhibitor treatment.

TNF-α inhibition improves clinical outcomes and has differential effects on haematopoiesis. Inflammation, therefore cytokines have important effects on hematopoietic system ([@b0060]). Increased platelet levels, erythrocyte sedimentation rate (ESR), normochromic normocytic anemia have been reported during active stages of AS ([@b0100]). Hematopoiesis would be improved with the remission of the inflammation by TNF-α inhibition. Anti-TNF-α therapy leads to some changes in hematological parameters such as such neutropenia and aplastic anemia ([@b0105], [@b0065]). But, there were few studies about the relationship between the blood eosinophil counts and TNF-α. It is known that eosinophils are generally associated with allergic and parasitic disorders. Infectious or inflammatory processes markedly suppress eosinophil count. It is related to the bone marrow suppression and blocking the release of mature eosinophils from the bone marrow. Also, stress may lead to decreases in the number of eosinophils due to epinephrine and glucocorticoids ([@b0135], [@b0070]).

To the best of our knowledge, the association between blood eosinophil counts, disease activity, and TNF-inhibition has not been reported in AS patients. The purpose of this study was to investigate the possible role of TNF on eosinophil counts and determine the relationship of TNF-α inhibition and eosinophil counts on inflammatory markers and disease activity.

2. Materials and methods {#s0010}
========================

Seventy-five patients fulfilled the modified New York criteria were enrolled the study, retrospectively. All AS patients were refractory to conventional therapy for at least three months and treated with Anti-TNF-α therapy (adalimumab = 15, certolizumab pegol = 8, etanercept = 14, golimumab = 14, infliximab = 24). Disease activity was determined by Bath ankylosing spondylitis Disease Activity Index (BASDAI) score in AS patients ([@b0045]). Refractory patients were defined as BASDAI score \> 4. Patients with the medical history of systemic diseases (dyslipidemia, diabetes mellitus, hypertension, hepatic-renal-vascular-cardiac disease, asthma, chronic obstructive pulmonary disease), infections, malignancies, smoking, treatment with corticosteroids, and modification on the treatment during the period of this study were excluded from the study. The study protocol was approved by the Ethics Board of our University.

The patients' demographic data, laboratory results, physical examination and disease activity of all patients (complete blood count, ESR, C-reactive protein (CRP), renal and hepatic function tests) of patients were extracted from patients' medical records. Whole blood cell count was measured by Coulter Gene-S instrument (Beckman Coulter, California, USA). Statistical Package for Social Sciences (SPSS) version 19.0 software was used for statistical analysis. Kolmogorov-Smirnov test was used to determine the distribution of normality. Descriptive data were displayed as mean ± standard deviation, median, minimum, maximum, and percentage values. Spearman's correlation and Friedman\'s Two-Way were used to comparing variables of patients and determine the correlation between BASDAI, ESH, CRP and blood eosinophil count. p-value of \< 0.05 was considered as statistically significant.

3. Results {#s0015}
==========

In this study, 75 AS patients were evaluated. Of 75 patients, 27 (36%) were female and 48 (64%) were male. The mean age of AS was 41 ± 10 years. Demographic features, disease activity score and laboratory findings of AS patients are shown in [Table 1](#t0005){ref-type="table"}. BASDAI score, the levels of ESR and CRP were statistically significantly different between pre- and post-treatment. After the anti-TNF-α therapy, levels of ESR, CRP, and the mean BASDAI score decreased significantly. The median BASDAI score decreased significantly on the 3th month (5.4 \[5.1--5.9\] vs 3.2 \[3--3.7\]; p ≤ 0001) and 6th month (5.4 \[5.1--5.9\] vs 2.8 \[2.6--3.2\]; p ≤ 0001) of treatment compared to baseline. The initial BASDAI score was correlated with CRP (r = 0.32, p = 0004), while there was no correlation between ESR and BASDAI score (r = 0.17, p = 0.1). On the 3th month of anti-TNF-α therapy, there was a correlation between BASDAI and CRP (r = 0.32, p = 0005), but no correlation was found between BASDAI score and ESR (r = 0.21, p = 0.06). But, there was a correlation between BASDAI score and ESR on the 6th month of anti-TNF-α therapy (r = 0.33, p = 0.03).Table 1Demographic features of patients with ankylosing spondylitis.Clinical characteristicsAnkylosing spondylitis (n:75)Age (year ± SD)41 ± 10  Gender n (%)Female27 (36%)Male48 (64%)  Biological agents (%)Adalimumab15 (20%)Certolizumab pegol8 (10.7%)Etanercept14 (18.7%)Golimumab14 (18.7%)Infliximab24 (32%)

Blood eosinophil counts did not correlate with BASDAI score, ESR and CRP before and after anti-TNF-α therapy (p \> 0.05). Initial median blood eosinophil count of AS patients were 130/mm^3^ (90--210/mm^3^) and 140/mm^3^ (100--200/mm^3^) on the 3rd month and 190 (110--240) on the 6th month of anti-TNF-α therapy. It counts lower before anti-TNF-α therapy when compared to post-treatment. There was no statistically significant difference between pre- and on the 3rd month (p \> 0.05), while statistically significant difference was found between pre- and on the 6th months, and also on the 3rd month and on the 6th month (p \< 0001, p = 0002, respectively) of anti-TNF-α therapy for blood eosinophil counts ([Table 2](#t0010){ref-type="table"}). The median eosinophil count was determined within normal ranges before and after (on the 3rd and 6th month) anti-TNF-α therapy. However, eosinophilia (770/mm^3^) was observed in a patient receiving golimumab on the 3rd month, but it was within normal ranges on the 6th month of anti-TNF-α therapy. Statistical analysis of changes in blood eosinophil count with each anti-TNF-α agent is shown in [Table 3](#t0015){ref-type="table"}.Table 2The distribution of ESR, CRP, BASDAI score and blood eosinophil count and their relationship with treatment.AS pre-treatment n = 75AS post-treatment (3th month)AS post-treatment (6th month)ESR (mm/h)35 \[16--50.5\]29 \[21--51\]23 \[12--33\]CRP (mg/dL)10.2 \[4.3--21.6\]9 \[4.4--13.6\]4.1 \[1.5--8.1\]BASDAI score5.4 \[5.1--5.9\]3.2 \[3--3.7\]2.8 \[2.6--3.2\]Eosinophil count (/mm^3^)130 \[90--210\]140 \[100--200\]190 \[110--240\][^1]Table 3Statistical analysis of changes in blood eosinophil count with each anti-TNF-α agent.p-value (0--3 month)p-value (3--6 month)p-value (0--6 month)Adalimumab10.070.03[\*](#tblfn1){ref-type="table-fn"}Certolizumab pegol0.118Etanercept10.420.002[\*](#tblfn1){ref-type="table-fn"}Golimumab0.291Infliximab\<0.001[\*](#tblfn1){ref-type="table-fn"}[^2]

4. Discussion {#s0020}
=============

The aim of AS treatment is to control inflammatory process, prevent functions, and improve the quality of life. Physical therapy, non-steroidal anti-inflammatory drugs, slow-acting anti-rheumatic drugs (conditionally, in patients with peripheral arthritis), and systemic glucocorticoids (conditionally, in patients with peripheral arthritis or during pregnancy) have used for effective control of AS ([@b0145]). Anti-TNF-α therapy has achieved an important position for the treatment of AS since 15 years. Anti-TNF-α therapy (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab) are now widely used for active AS patients who fail to NSAIDs. All AS patients of this study were refractory to conventional therapy for at least 3 months. TNF-α inhibitors have improved clinical symptoms in AS patients with persistently high disease activity. In this study, BASDAI decreased with anti-TNF-α therapy on the 3rd and 6th month of treatment compared with baseline. Safety and side effect have been discussed with the increasing use of Anti-TNF-α agents such as infections, immunogenicity, injection site reaction, lupus-like reactions, and exacerbation of heart failure ([@b0110]). Also, leukopenia, thrombocytopenia ([@b0010]), neutropenia ([@b0160]), severe pancytopenia ([@b0090]), and severe neutrophilia ([@b0025]) have been reported with anti-TNF-α therapy. In our study, no side effect was found with TNF-α inhibitors on the follow-up. However, eosinophilia was observed in a patient receiving golimumab on the 3rd month, but it was within normal ranges on the 6th month of anti-TNF-α therapy.

TNF-α is an important cytokine in the pathogenesis of AS. TNF-α is a homotrimer, biologically active protein, consisting of 2 forms (17-kDa-secreted, 26-kDa-cell-associated), and predominantly produced by activated macrophages and T lymphocytes. It is thought that membrane TNF-α is associated with signaling secondary to cellular contact. TNF-α should bind to the receptors to activate intracellular pathways for biological effects ([@b0005]). TNF-α has higher affinity to TNF receptor 2 (TNFR2-p75-CD120b without death domain) than TNFR1 (p55-CD120a). While TNFR1 has dual signaling pathway including survival (due to TNFR-associated factor-2), and apoptotic or cellular death (due to Fas-associated death-domain-containing protein and TNFR1-associated death-domain-containing protein), TNFR2 is associated with homeostasis, regeneration and immune regulation ([@b0120], [@b0130]). TNF-α is bifunctional on hematopoiesis like growth enhancer at low concentrations and inhibitor of bone marrow progenitors. The regulation of stem cells are complex, and it is difficult to predict. TNFR2 appears to be restricted to inhibitory effects on primitive hematopoietic progenitors ([@b0065], [@b0060]). So, TNF-α inhibition may lead to the recovery of the hematopoietic system ([@b0060], [@b0015]).

Aplastic anemia ([@b0065]), leukopenia, thrombocytopenia ([@b0010]), neutropenia ([@b0160]), severe pancytopenia ([@b0090]), and severe neutrophilia ([@b0025]) have been reported with adalimumab, etanercept, and infliximab. Although neutrophil autoantibodies ([@b0025]), inhibition of neutrophil chemotaxis or stem cell differentiation are suspected as the cause of neutropenia ([@b0160], [@b0090]), the mechanism is unclear. Also, other abnormalities about granulocytic series such as eosinophilia have been reported. According to the eHealthMe database ([@b0030]), 0.06% of patients who have side effects due to adalimumab have eosinophilia with the female predominance [@b0140]. The rate of reported side effect is 0.03% for etanercept, 0.07% for infliximab, and 0.04% for golimumab. No report has been found about certolizumab ([@b0055], [@b0030]). In our study, eosinophilia was observed in a patient on the 3rd month of golimumab. But, eosinophil count was within normal ranges before and on the 6th month of anti-TNF-α therapy. The patient had no medical history of atopy. The parasite screen was negative and total IgE levels and hematological profile (except for eosinophilia) were within normal ranges.

Peripheral blood eosinophil count is a valuable biomarker for allergic diseases, parasitic infections, asthma, hypereosinophilic syndrome and sepsis. The formation and migration of eosinophil are suppressed due to inflammation in bone marrow ([@b0070]). Both of Nuclear Factor-κB (NF-κB) and TNF-α have an important role in the regulation of cellular death ([@b0140], [@b0095]). TNF-α induces cytoplasmic IkBα (inhibitor subunit of NF-kB) degradation in eosinophils. In a study, it was reported that TNF-α-induced apoptosis is up-regulated by gliotoxin in eosinophils ([@b0040]). Eosinophils express TNFR1 and TNFR2, and their activation is thought to promote eosinophil apoptosis. Otherwise, TNF-α has been reported to be associated with eosinophil survival through the granulocyte-macrophage colony-stimulating factor and p38 kinase pathway ([@b0140], [@b0155]). Also, the level of eosinophil cationic protein that is a specific protein of eosinophil decrease with sulfasalazine treatment ([@b0035]).

In a patient with rheumatoid arthritis (RA), perivascular and interstitial eosinophilic infiltrates were observed in the histologic dermal specimen of developing skin reactions with etanercept ([@b0090]). The etiopathogenesis is not known whether with etanercept or component of the vehicle. Transient blood eosinophilia with adalimumab was reported ([@b0150]). It was mentioned that type I and type III hypersensitivity reactions might be related to adalimumab-associated eosinophilic cellulitis. Also, case series were of eosinophilia reported during psoriasis treatment with adalimumab ([@b0020]). Eosinophilia, elevated immunoglobulin E, and development of asthma has been reported in RA patients with the treatment of adalimumab. The clinical outcomes were thought to be as a result of activated Th2 pathway due to suppression of Th1 (shifting Th1 to Th2 phenotype) by TNF-α inhibition. There was reported 3 cases with eosinophilia during psoriasis treatment with TNF-α inhibitors in the literature ([@b0085]). The first case had relative eosinophilia and history of allergic rhinitis before adalimumab. On the 3.25 months of treatment, the patients' eosinophil count was 1.550/µg/L with normal IgE and no evidence for paracytic and hematological disorders. In the second patient, eosinophilia was developed on the 8.5th month of adalimumab. And, eosinophilia was developed in another atopic patient with adalimumab and etanercept therapy. Eosinophil counts returned to normal ranges with the discontinuation of the suspected drug in all patients. In another patient diagnosed with rheumatoid arthritis, peripheral eosinophilia and eosinophilic infiltrates were detected in the biopsy of patients' papulovesicular lesion after infliximab treatment. Eosinophilia was observed in the same patient due to switching infliximab to etanercept.

The specificity and sensitivity of CRP and ESR used to assess the disease activity is low in patients with spondyloarthropathies ([@b0125]). An easy, practical, and objective biomarker has always been a research topic. Therefore, neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), mean platelet volume (MPV) ([@b0125]), pentraxin-3 ([@b0115]), and intercellular adhesion molecules ([@b0080]) have been investigated as disease activity markers in patients with spondyloarthritis. Significant correlations between disease activity and ICAM-2, but not ICAM-1 levels reported in a study ([@b0080]). However, there was no significant correlation between disease activity and NLR, PLR, MPV ([@b0125]), pentraxin-3 ([@b0115]). In our study, there was a decrease in the BASDAI score and increase in the number of eosinophil count with anti-TNF-α therapy. However, no correlation of eosinophil count with BASDAI was observed. Therefore, eosinophil count cannot be used as a biomarker that reflects disease activity.

5. Conclusion {#s0025}
=============

The present study has demonstrated that eosinophil count was increased on the 3rd and 6th month in AS patients treated with anti-TNF-α agents. Blood eosinophil count may be affected by TNF-α inhibition in patients with AS. To the best of our knowledge, our study is the first to evaluate blood eosinophil counts, disease activity with anti-TNF-α therapy. The limitation of our study is the long-term results of this study are not known. Nevertheless, comprehensive prospective studies with large number of patients are needed to confirm relationship between disease activity.
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[^1]: ESR: erythrocyte sedimentation rate, CRP: C-reactive protein, BASDAI: Bath ankylosing spondylitis disease activity index, median and interquartile range \[25^th^--75th percentile\].

[^2]: p-value of \<0.05 was considered as statistically significant.
